Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Cuthbertson et al., 2009)
Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on Wednesday that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for its GLP-1 obesity drug efpeglenatide and its Dapalon-lineup diabetes treatment combination products
These medications can also be beneficial for people with obesity or those who need help managing their weight due to other health conditions
By doing so, it helps individuals feel satisfied sooner during meals, leading to reduced calorie intake over time
Implications for treatment selection As combination products become more common, the distinction between insulin and GLP-1 therapy becomes more important, not less
US$ 23.36
US$ 28.00
US$ 20.51
US$ 21.21
US$ 21.43
